Blocking TLR4-associated nuclear factor κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathway activation or recovering the polarization of macrophages from an M1-type proinflammatory phenotype to an M1-type anti-inflammatory phenotype could both alleviate experimental colitis (Tang 2019). This evidence concerns the gene NFKB1 and colitis.